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Background: Both hyperlactatemia and persistence of hyperlactatemia have been associated with bad outcome.
We compared lactate and lactate-derived variables in outcome prediction.
Methods: Retrospective observational study. Case records from 2,251 consecutive intensive care unit (ICU) patients
admitted between 2001 and 2007 were analyzed. Baseline characteristics, all lactate measurements, and in-hospital
mortality were recorded. The time integral of arterial blood lactate levels above the upper normal threshold of 2.2
mmol/L (lactate-time-integral), maximum lactate (max-lactate), and time-to-first-normalization were calculated.
Survivors and nonsurvivors were compared and receiver operating characteristic (ROC) analysis were applied.
Results: A total of 20,755 lactate measurements were analyzed. Data are srpehown as median [interquartile range].
In nonsurvivors (n = 405) lactate-time-integral (192 [0–1881] min·mmol/L) and time-to-first normalization (44.0
[0–427] min) were higher than in hospital survivors (n = 1846; 0 [0–134] min·mmol/L and 0 [0–75] min, respectively; all
p < 0.001). Normalization of lactate <6 hours after ICU admission revealed better survival compared with normalization
of lactate >6 hours (mortality 16.6% vs. 24.4%; p < 0.001). AUC of ROC curves to predict in-hospital mortality was the
largest for max-lactate, whereas it was not different among all other lactate derived variables (all p > 0.05). The area
under the ROC curves for admission lactate and lactate-time-integral was not different (p = 0.36).
Conclusions: Hyperlactatemia is associated with in-hospital mortality in a heterogeneous ICU population. In our
patients, lactate peak values predicted in-hospital mortality equally well as lactate-time-integral of arterial blood lactate
levels above the upper normal threshold.
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Hyperlactatemia is common in critically ill patients and
may reflect an imbalance between local or systemic oxy-
gen supply (DO2) and oxygen consumption (VO2).
Hyperlactatemia also may be found during increased
aerobic glycolysis in hypermetabolic states from various
causes [1,2], in patients treated with catecholamines
[3,4], as a consequence of alkalosis in hyperventilation
[5], and with impaired hepatic lactate clearance in sepsis
or low flow states [6]. Elevated lactate levels are
associated with the development of multiple organ dys-
function (MODS) postoperatively, following trauma, and* Correspondence: p.van.beest@umcg.nl
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in any medium, provided the original work is pseptic shock [7-10], and it has been suggested that
hyperlactatemia is associated with worse outcome
[10-13]. Persistence of lactate levels above normal is
associated with higher mortality rates in patients with
severe sepsis, septic shock [9,14], and in postcardiac
arrest patients [15].
We hypothesized that the severity of persistent
hyperlactatemia represented by the time integral of arterial
blood lactate levels above the upper normal threshold of
2.2 mmol/L (lactate-time-integral) outperforms single
lactate measurements in predicting outcome. We there-
fore retrospectively investigated the relationship between
lactate derived variables (admission level, maximum level,
time-to-first-normalization, lactate-time-integral) and in-
hospital mortality in a large, mixed intensive care unit
(ICU) population. Subgroup analysis was performed onis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Baseline and clinical characteristics
Characteristic All Survivors Nonsurvivors p
valuean = 2,251 n = 1846 n = 405
Age (yr) 66 (12–98) 69 (57–76) 75 (67–81)
Sex M : F (%) 61 : 39 61 : 39 60 : 40
SAPS-II 38 (20–113) 33 (24–43) 51 (41–65) <0.001*
SOFA




Emergency 20.2 20.4 19.3
Surgical / OR 43.7 47.3 27.0
Medical 27.2 23.7 43.1
CCU 8.0 7.5 10.1
Other 0.9 1.1 0.5
Diagnosis (%) <0.01#*




Other surgery 9.8 10.9 4.9




GI bleeding 3.8 4.3 1.5
Neurological 4.5 4.6 2.7
Other 3.7 3.9 4.2
Sepsis 13.1 11.8 19.2
Vasoactive
agent (%)
33 28 57 <0.001*
LOS ICU (days) 2 (1–5) 2 (1–5) 3 (1–8) <0.001*




Data are presented as numbers and median (interquartile range). AUC, area
under the curve; SAPS-II, simplified acute physiology score; APACHE II, acute
physiology, age and chronic health evaluation; OR, operating room; CCU, cardiac
care unit; GI, gastrointestinal; vasoactive agent: noradrenaline, dopamine,
dobutamine, phosphodiesterase inhibitor; LOS ICU, length of stay at intensive
care; LOS HOSP, length of stay at hospital; aSurvivors vs. nonsurvivors; bAll normal
lactate (AUC = 0) vs. all elevated lactate (AUC > 0); *Statistically significant
difference. Statistics by Chi-square tests# and Wilcoxon rank-sum tests.
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of mortality (sepsis and circulatory failure) [10-13]. Add-
itionally, we looked at possible differences between




A retrospective, observational study in a university-
affiliated teaching hospital where the ICU is a mixed,
ten-bed, “closed format” department. There were no
changes in medical staff during the study period. Case
records from all ICU patients with available lactate
measurements admitted during a 5-year period, January
2002 to December 2006, were identified in the ICU data-
base. The study was approved by the Local Ethics Com-
mittee, which waived the need for informed consent.
Data collection
Data from all days spent in the ICU were collected retro-
spectively from the electronic patient data monitoring
system and the hospital administration database. We
collected demographic information, diagnosis, acute
physiology and chronic health evaluation (APACHE II), all
lactate levels, and relevant variables for calculation of daily
assessed SOFA score (Table 1). Diagnosis classifications
were based on the APACHE II classifications, hence diag-
nosis category weight [17]. Finally, length of stay in the
ICU (LOSICU), days in the hospital before discharge
(LOSHOSP), and hospital survival were recorded.
Lactate levels and derived variables
Lactate levels were measured in arterial blood using
point-of-care blood gas analyzers (Rapidlab 865, Siemens,
Munich, Germany; upper normal limit 2.2 mmol/L). The
time integral for lactate levels above the upper normal
threshold of 2.2 mmol/L was calculated during the entire
ICU stay (lactate-time-integral) using custom-made
software. We used a formula that, for practical reasons,
assumed a linear change over time between measurements.
Figure 1 illustrates four possible scenarios used for calcu-
lating lactate-time-integral.
Lactate buffer solutions for renal replacement therapy
(RRT) and continuous epinephrine infusion were not
used during the study period following the general policy
in the unit.
Statistical analysis
The statistical package for the social sciences (SPSS
16.0.1 for Windows, Chicago, IL) was used for statistical
analyses and additional software was used for graphics
(Prism 5.0 for windows, La Jolla, CA) and comparison of
ROC curves (MedCalc 11.2.1, Mariakerke, Belgium). Data
are presented as mean ± SD or median [interquartilerange] as indicated by assessment of normal distribu-
tion (D’Agostino-Pearson omnibus normality test).
Mann–Whitney U test was used for not normally
distributed data. Differences of admission source or
admission diagnosis between groups of survivors and
nonsurvivors and those with and without hyperlactatemia
were assessed using the Chi-square test. Receiver operat-
ing characteristic (ROC) curves were used for the assess-
ment of sensitivity and specificity of lactate-derived
variables to predict in-hospital mortality. Areas under the
ROC curves (AUCROC) were compared by the method
Figure 1 Calculation of lactate area under the curve above the
upper normal limit of lactate (2.2 mmol/L). The following four
equations were used in computing lactate-AUC: 1) AUC A = ((½ ·
(lactate 0 – lactate 1)) + lactate 1)) · (time 1 – time 0); 2) AUC
B = ((½ · (lactate 2 – lactate 1)) + lactate 1)) · (time 2 – time 1); 3)
AUC C = ((lactate 2 – 2.2)2 · (time 3 – time 2)) / 2 · lactate 2; 4) AUC


























































Figure 2 Admission lactate levels (mmol/L), maximum lactate
levels (mmol/L), time-to-normal (min) for survivors (n = 1.846)
and nonsurvivors (n = 405). Bars show median (upper interquartile
range); Mann–Whitney test; logarithmic scale.
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assumed at p < 0.05.
Results
During the 5-year period, case records of 2,251 patients
(age 66 [12–98] years; 39% female) were identified. From
all patients, at least one lactate sample was drawn and
therefore none of the patients was excluded. A total of
20,755 lactate measurements were analyzed. Median
lactate samples per day per patient was 2.0 [1.0-5.0]
samples. Median lactate concentration at admission was
1.7 [1.1-2.8] mmol/L; minimum 0.6 mmol/L and max-
imum 27.0 mmol/L. Median max-lactate was 2.1 [1.5-3.3]
mmol/L, and median lactate-time-integral 0.0 [0.0-244]
min·mmol/L. Baseline and clinical characteristics of all
patients are summarized in Table 1.
In-hospital mortality of our population was 18% and
was higher in patients with hyperlactatemia during ICU
stay compared with those without hyperlactatemia
(26.4% vs. 10.8%; p < 0.001). Survival was significantly
higher in patients with lactate normalization within 6
hours after ICU admission (n = 1,856) compared with
patients with lactate normalization >6 hours after ICU
admission (n = 395; 16.6% vs. 24.4%; p < 0.001). For
patients who died in the hospital (n = 405), admission
lactate (2.6 [1.5-5.0] mmol/L), max-lactate (3.2 [1.9-5.8]
mmol/L) time-to-first-normalization (44.0 [0–427] min),
and lactate-time-integral (192 [0–1,881] min·mmol/L),
were higher than in-hospital survivors (n = 1,846;
admission lactate (1.6 [1.1-2.5] mmol/L), max-lactate
(2.0 [1.4-3.0] mmol/L), time-to-first-normalization
(0.0 [0–75] min) and lactate-time-integral 0 [0–134]min·mmol/L, respectively; all p < 0.001; Figure 2).
Subanalysis for the first 24 hours showed similar
results; all p < 0.001.
Figure 3 demonstrates the difference between admission
lactate levels and lactate-derived variables with respect to
predicting in-hospital mortality. AUCROC for admission
lactate and lactate-time-integral were similar (0.666 [95%
confidence interval (CI) 0.646-0.686] vs. 0.676 [95% CI
0.657-0.696]; p = 0.36). AUCROC for max-lactate (0.692
[95% CI 0.672-0.711]) was larger than AUCROC for admis-
sion lactate (0.666 [95% CI 0.646-0.686]; p = 0.01) lactate-
time-integral (0.676 [95% CI 0.657-0.696]; p < 0.01), and
Figure 3 Receiver operating characteristic curves for in-hospital
mortality prediction. Area under the curve was 0.552 for time-to
-first-normalization, 0.666 for admission lactate, 0.676 for lactate-time
-integral and 0.692 maximum lactate.

















AUC ROC, area under receiver operating characteristic curve; alactate threshold
presented in mmol/L; bnormalization to respective threshold.
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ROC curves for all four variables were significantly differ-
ent from the reference line (all p < 0.01). The cutoff points
derived from the ROC curve for admission lactate,
max-lactate and cumulative lactate were 2.7 mmol/L,
2.5 mmol/L, and 53 min·mmol/L, respectively. AUCROC
lactate-time-integral per day was (0.672 [95% CI 0.641-
0.694]; figure not shown).
AUCROC for both time to normal and lactate-time-
integral were also calculated with other thresholds
(thresholds 1.0 mmol/L, 2.0 mmol/L, 3.0 mmol/L, and
4.0 mmol/L respectively). Table 2 summarizes the results
for both total population and subgroups. None of these
AUCROC were significantly different from the reference
line (all p > 0.05).
In none of the subgroups (sepsis, n = 307; cardiac failure,
n = 213; Table 3) AUCROC for lactate-time-integral was
larger than AUCROC for single lactate values. In both
subgroups admission lactate, maximum lactate and
lactate-time-integral differed between survivors and
nonsurvivors (all p < 0.001). Analysis for the first 24
hours after admission showed similar results; in both
subgroups all p < 0.01.
Discussion
In the present study, lactate-time-integral was not super-
ior in predicting in-hospital mortality compared with ad-
mission or maximum arterial lactate concentrations.
Elevated admission lactate values, maximum lactate
values during ICU stay, time-to-first-normalization, andlactate-time-integral were all associated with in-hospital
mortality. Data on the first 24 hours after admittance
revealed similar results: lactate derived variables were
significantly higher in nonsurvivors compared with
survivors. However, the “dynamic” lactate index, i.e.,
lactate-time-integral, did not outperform the “static”
lactate variables, i.e., admission lactate and maximum
lactate.
High lactate clearance within the first 6 hours has
been shown to be associated with decreased 60-day mor-
tality, even in the absence of arterial hypotension;
survivors compared with nonsurvivors had a lactate
clearance of 38 vs. 12%, respectively [14]. The present
results also show a survival benefit for patients with lac-
tate normalization within 6 hours in a heterogeneous
ICU population. Recently, in a randomized study, the
use of lactate clearance was described as an efficacious
alternative for ScvO2-guided (target > 70%) resuscitation
of patients in septic shock [19]. However, due to prac-
tical reasons, a treatment bias could not be excluded.
Also, difference in protocol actions was small; despite a
well-performed study, chance may have influenced the
results. In the present study, we did not evaluate lactate
clearance as described in septic patients by Nguyen et al.
[14], i.e., as a ratio of lactate values. Instead, we
evaluated a combination of the lactate-derived variables
as a surrogate for lactate clearance. However, in the sub-
group septic patients the lactate-time-integral or time-to
-first-normalization did not outperform max-lactate.
Lactime, described as a duration of hyperlactatemia, also
has been shown to be the best discriminator of survival
when the patients who died in the first 24 hours were
Table 3 Baseline and clinical characteristics subgroups
Characteristic Sepsis (n = 307) Cardiac failure (n = 213)
Age (yr) 69 [60–77] 72 [63–78]
Sex M : F (%) 63 : 37 60 : 40
SAPS II 48 [37–57] 48 [37–63]
APACHE II 21 [17-26] 22 [16–28]
Heart rate (beats/min) 115 [96–130] 110 [80–125]
Systolic blood pressure (mmHg) 105 [80–130] 110 [85–140]
Mean arterial pressure (mmHg) 58 [50–62] 59 [51–65]
Vasoactive agent (%) 56 56
Lactate (mmol/L) 2.4 [1.6-3.9] 2.4 [1.4-4.8]
Maximum lactate (mmol/L) 3.0 [2.1-4.9] 3.0 [1.9-5.2]
Cum-lactate (min·mmol/L) 216 [0–2634] 138 [0–1245]
In-hospital mortality (%) 29 38
Data are presented as numbers and median [interquartile range]. SAPS-II, simplified acute physiology score; APACHE II, acute physiology, age and chronic
health evaluation.
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choose not to exclude those patients who died early after
onset of the disease to picture the influence of lactate
and lactate-derived variables in clinical reality. In con-
clusion, the present results recognize the importance of
lactate clearance as described by others but also under-
line the importance of magnitude of lactate values dur-
ing ICU treatment. In other words, time to first
normalization may not be a key factor. This is clinically
important: we need continuous reassessment of lactate
levels to guide our resuscitation efforts.
A lactate threshold ≥4 mmol/L has been used to
initiate protocol-based resuscitation [20,21]. Such an
approach might imply acceptance of intermediate lactate
levels in the range of 2 to 4 mmol/L. However, elevated
mortality rates also are described in critically ill patients
with only moderately elevated lactate levels during or
even before admission to the emergency department
(ED) [22-24]. Additionally, in two recent retrospective
studies the relationship between lactate levels, lactate-
derived variables, and outcome in critically ill patients
was assessed. It was concluded that not only
hyperlactatemia but also relative hyperlactatemia, i.e.,
lactate levels in the upper normal range, are associated
with increased mortality [16,25]. Our results in ICU
patients are concordant with these results, and we be-
lieve that normal values provide a reasonable clinical
sign that tissue oxygenation is adequate and the metab-
olism is primarily aerobic. Of note, a higher lactate con-
centration threshold revealed different results: higher
thresholds did not enhance predictive value for outcome.
Indeed, not every hyperlactatemia is associated with
acidosis, which is an important contributor to worse
outcome. This might explain why lactate-time-integral
does not outperform peak lactate values in outcomeprediction in the present cohort. However, one could
argue on the clinical relevance of the significant yet
small difference in AUCROC of peak lactate and AUCROC
of lactate-time-integral (0.692 vs. 0.676; p < 0.01).
Definitive conclusions probably should not be made on
such small differences. On the other hand, our results
do not confirm superiority of dynamic lactate variables
over static lactate variables as suggested earlier [16].
In addition, two other factors may be responsible for
this finding. First, the retrospective design of our study
and the lack of a specific intervention protocol limits the
generalization of our results. Second, arterial lactate
concentrations not only depend on lactate production
but also on its clearance. It is not known whether one
mechanism is more important than the other with re-
spect to outcome prediction. Nevertheless, the mechan-
ism causing hyperlactatemia may play an important role
in outcome prediction, rather than the hyperlactatemia
itself. For instance, as described in two recent reports
[26,27], the severity of hyperlactatemia due to metformin
accumulation alone does not predict outcome but even
in those cases the causative role is uncertain. Also,
comorbidities, such as renal insufficiency of liver failure,
may play an additional role [26,27].
Finally, patients who died early, i.e., within 24 hours,
possibly could not accumulate enough lactate-time-inte-
gral values despite disease severity. Establishment of a
relationship between the lactate-time-integral and sur-
vival therefore could be disturbed. However, when the
length of ICU stay was taken into account, the AUCROC
was not larger and the lactate-time-integral per day did
not perform better than peak lactate.
Nonsurvivors revealed shorter LOSICU and LOSHOSP,
whereas lactate-time-integral was significantly higher in
nonsurvivors compared with survivors. The duration
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the area under the lactate curve, is associated with final
outcome. Nevertheless, in the present study, the specificity
and sensitivity, described by AUCROC, of admission lactate
and lactate-time-integral were similar in predicting in-
hospital mortality. However, the present results on this
large heterogeneous population underline the importance
of ongoing watchfulness during the entire ICU stay.
Several limitations to our observations should be
considered. First, this was a retrospective study, which
precludes definitive conclusions. Also, there was no pre-
defined lactate measurement or lactate-based goal-
directed protocol. However, we consider the results
strong enough to warrant further prospective studies
analyzing the described phenomena, particularly because
the data were collected over a 5-year period and derived
from a large group of patients. Second, this was a single-
unit study in one Dutch ICU, and therefore the results
may only reflect the regional population and ICU man-
agement strategies. Nevertheless, we believe that selec-
tion bias was minimized, because all consecutive
admissions were included in the data analysis and be-
cause there was no change in medical staffing, and ad-
mission and discharge criteria were stable during the
study period. Third, we assumed a linear change in time
between two lactate measurements, which is a simplifi-
cation of a real biologic process. However, we believe
that our approach represents an approximation with
acceptable precision for the purpose of the present study.
Conclusions
We conclude that hyperlactatemia is associated with in-
hospital mortality in a heterogeneous ICU population. In
our patients, lactate peak values predicted in-hospital
mortality equally well as lactate-time-integral of arterial
blood lactate levels above the upper normal threshold.
In a heterogeneous ICU population, normalization of
lactate within 6 hours is associated with lower mortality.
Thus, concerning lactate levels in a heterogeneous ICU
population magnitude matters and ongoing watchfulness
on elevated lactate levels is warranted for time to first
normalization may not be the key factor.
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